Tumor characteristics and survival rate of HER2-low breast cancer patients: a retrospective cohort study

被引:9
作者
Abbasvandi, Fereshteh [1 ,2 ]
Bayat, Mahdis [1 ]
Akbari, Atieh [1 ]
Shojaeian, Fatemeh [3 ]
Zandi, Ashkan [4 ]
Rahmani, Jamal [1 ]
Hashemi, Maryam Omrani [1 ]
Akbari, Mohammad Esmaeil [1 ]
机构
[1] Shahid Beheshti Univ Med Sci, Shohadaye Tajrish Hosp, Canc Res Ctr, Tehran, Iran
[2] ACECR, Motamed Canc Inst, Breast Canc Res Ctr, ATMP Dept, POB 1517964311, Tehran, Iran
[3] Johns Hopkins Univ, Dept Surg, Sch Med, Baltimore, MD USA
[4] Georgia Inst Technol, Sch Elect & Comp Engn, Atlanta, GA 30332 USA
关键词
EXPRESSION; LEVEL;
D O I
10.1038/s41598-023-43186-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
HER2 is an important prognostic marker in breast cancer (BC) patients, which also plays a crucial role in their therapeutic plan. Consequently, a great desire is to thoroughly assess the patients based on their HER2 status. In the current study, we aimed to evaluate HER2-low breast cancer as a new subtype in the standard classification of BC patients and review its characteristics and survival rate in a tertiary center in Iran. We retrospectively evaluated disease-free survival (DFS), overall survival (OS), and clinicopathological characteristics of BC patients referred to the Cancer Research Center in Tehran, Iran from 1991 to 2022. Patients' clinical characteristics, including HER2 status, which is classified as HER2-low, HER2-positive, or HER2-negative, were obtained from prospectively maintained registries. Among the total 3582 recruited patients, 60.2%, 13.6%, and 26.2% were HER2-negative, HER2-low, and HER2-positive, respectively. HER2-positive patients showed a significantly higher Hazard Ratio (HR) for DFS (HR 1.44, 95% CI 1.01-2.05) and OS (HR 2.05, 95% CI 1.31-3.20), compared to HER2-low. Moreover, HER2-low and HER2-negative were found to show the same proportion of high-grade tumors (28 and 28.4%), while 40% of the HER2-positive tumors were high-grade. Accordingly, HER2-low patients had a lower metastasis risk than the others (P-value = 0.01). The Ki67 percentage was significantly lower in the HER2-low group compared to the HER2-positive (P-value < 0.001). HER2-low, a new subtype of HER2-status classification with distinct biological and clinicopathological traits, represented the highest survival rate and less invasive characteristics. This difference was statistically significant when compared to HER2-positive, but not when compared to HER2-negative.
引用
收藏
页数:10
相关论文
共 30 条
[1]   HER2-Low Breast Cancer: Molecular Characteristics and Prognosis [J].
Agostinetto, Elisa ;
Rediti, Mattia ;
Fimereli, Danai ;
Debien, Veronique ;
Piccart, Martine ;
Aftimos, Philippe ;
Sotiriou, Christos ;
de Azambuja, Evandro .
CANCERS, 2021, 13 (11)
[2]   The new TNM-based staging of breast cancer [J].
Cserni, Gabor ;
Chmielik, Ewa ;
Cserni, Balint ;
Tot, Tibor .
VIRCHOWS ARCHIV, 2018, 472 (05) :697-703
[3]   Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials [J].
Denkert, Carsten ;
Seither, Fenja ;
Schneeweiss, Andreas ;
Link, Theresa ;
Blohmer, Jens-Uwe ;
Just, Marianne ;
Wimberger, Pauline ;
Forberger, Almuth ;
Tesch, Hans ;
Jackisch, Christian ;
Schmatloch, Sabine ;
Reinisch, Mattea ;
Solomayer, Erich F. ;
Schmitt, Wolfgang D. ;
Hanusch, Claus ;
Fasching, Peter A. ;
Luebbe, Kristina ;
Solbach, Christine ;
Huober, Jens ;
Rhiem, Kerstin ;
Marme, Frederik ;
Reimer, Toralf ;
Schmidt, Marcus ;
Sinn, Bruno, V ;
Janni, Wolfgang ;
Stickeler, Elmar ;
Michel, Laura ;
Stoetzer, Oliver ;
Hahnen, Eric ;
Furlanetto, Jenny ;
Seiler, Sabine ;
Nekljudova, Valentina ;
Untch, Michael ;
Loibl, Sibylle .
LANCET ONCOLOGY, 2021, 22 (08) :1151-1161
[4]   The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies [J].
Freudenberg, Jaclyn A. ;
Wang, Qiang ;
Katsumata, Makoto ;
Drebin, Jeffrey ;
Nagatomo, Izumi ;
Greene, Mark I. .
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2009, 87 (01) :1-11
[5]   Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry [J].
Gampenrieder, Simon Peter ;
Rinnerthaler, Gabriel ;
Tinchon, Christoph ;
Petzer, Andreas ;
Balic, Marija ;
Heibl, Sonja ;
Schmitt, Clemens ;
Zabernigg, August Felix ;
Egle, Daniel ;
Sandholzer, Margit ;
Singer, Christian Fridolin ;
Roitner, Florian ;
Hager, Christopher ;
Andel, Johannes ;
Hubalek, Michael ;
Knauer, Michael ;
Greil, Richard .
BREAST CANCER RESEARCH, 2021, 23 (01)
[6]   Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer [J].
Gilcrease, Michael Z. ;
Woodward, Wendy A. ;
Nicolas, Marlo M. ;
Corley, Lynda J. ;
Fuller, Gregor N. ;
Esteva, Francisco J. ;
Tucker, Susan L. ;
Buchholz, Thomas A. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2009, 33 (05) :759-767
[7]   In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+and HER2 2+/Her2 amplified cases [J].
Giuliani, Silvia ;
Ciniselli, Chiara Maura ;
Leonardi, Elena ;
Polla, Enzo ;
Decarli, Nicola ;
Luchini, Claudio ;
Cantaloni, Chiara ;
Gasperetti, Fabio ;
Cazzolli, Daniela ;
Berlanda, Gabriella ;
Bernardi, Daniela ;
Pellegrini, Marco ;
Triolo, Renza ;
Ferro, Antonella ;
Verderio, Paolo ;
Barbareschi, Mattia .
VIRCHOWS ARCHIV, 2016, 469 (01) :45-50
[8]   HER2-low breast cancer could be associated with an increased risk of brain metastasis [J].
Guven, Deniz Can ;
Kaya, Mehmet Burak ;
Fedai, Burak ;
Ozden, Mucahit ;
Yildirim, Hasan Cagri ;
Kosemehmetoglu, Kemal ;
Kertmen, Neyran ;
Dizdar, Omer ;
Uner, Aysegul ;
Aksoy, Sercan .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (02) :332-339
[9]   Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status [J].
Hein, Alexander ;
Hartkopf, Andreas D. ;
Emons, Julius ;
Lux, Michael P. ;
Volz, Bernhard ;
Taran, Florin-Andrei ;
Overkamp, Friedrich ;
Hadji, Peyman ;
Tesch, Hans ;
Haeberle, Lothar ;
Ettl, Johannes ;
Lueftner, Diana ;
Wurmthaler, Lena A. ;
Wallwiener, Markus ;
Mueller, Volkmar ;
Beckmann, Matthias W. ;
Belleville, Erik ;
Wimberger, Pauline ;
Hielscher, Carsten ;
Kurbacher, Christian M. ;
Wuerstlein, Rachel ;
Thomssen, Christoph ;
Untch, Michael ;
Fasching, Peter A. ;
Janni, Wolfgang ;
Fehm, Tanja N. ;
Wallwiener, Diethelm ;
Brucker, Sara Y. ;
Schneeweiss, Andreas ;
Kolberg, Hans-Christian .
EUROPEAN JOURNAL OF CANCER, 2021, 155 :1-12
[10]   The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status [J].
Horisawa, Nanae ;
Adachi, Yayoi ;
Takatsuka, Daiki ;
Nozawa, Kazuki ;
Endo, Yuka ;
Ozaki, Yuri ;
Sugino, Kayoko ;
Kataoka, Ayumi ;
Kotani, Haruru ;
Yoshimura, Akiyo ;
Hattori, Masaya ;
Sawaki, Masataka ;
Iwata, Hiroji .
BREAST CANCER, 2022, 29 (02) :234-241